Ovarian Clear Cell Carcinoma clinical trials at UC Irvine
1 research study open to eligible people
Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Platinum-doublet + Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (OnPrime, GOG-3076)
open to eligible females ages 18 years and up
The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with platinum-doublet chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer).
Orange, California and other locations
Our lead scientists for Ovarian Clear Cell Carcinoma research studies include Krishnansu S. Tewari, MD.